Skip to content

MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery

A Double-blind Randomized Trial of Interpectoral Nerve Block (Pecs 1 and 2) With Ropivacaine Versus Placebo Before Breast Cancer Surgery: Effects on Acute Postoperative Pain. (MIRs 04)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04327063
Acronym
MIRs 04
Enrollment
182
Registered
2020-03-30
Start date
2020-08-04
Completion date
2022-01-28
Last updated
2025-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Neoplasm of Breast

Keywords

Surgery conservative, Nerve block

Brief summary

Compare the effect of ropivacaine versus placebo pectoral nerve block (Pecs 1 and 2) on acute pain after tumorectomy plus sentinel lymph node dissection on one day surgery.

Detailed description

Before surgery, the 3rd interpectoral space will be identified. After aspiration, half of the solution of Ropivacaine 5 mg/ml not exceeding 3 mg/kg of maximal dose and 30 ml of maximal volume or saline (not exceeding 30 ml of maximal volume) will be injected into the interpectoral space underneath the pectoralis major muscle for the Pecs 1 block. The other half of the solution will be injected above the serratus anterior muscle at the third rib. Evaluation of the percentage of patients treated with step 2 or 3 analgesics during the three postoperative hours.

Interventions

DRUGSaline

Injection of the solution of Saline not exceeding 30 mL of maximal volume.

DRUGRopivacaine

Dilution of Ropivacaine 7.5 mg/ml to 5 mg/ml not to exceed 3 mg/kg of maximal dose and 30 ml of maximal volume

Sponsors

Institut Curie
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

Double

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Women with non-metastatic invasive breast carcinoma or breast carcinoma in situ treated by breast-conserving surgery (tumorectomy) with sentinel node technique on one day surgery. 2. Age between 18 and 85 years. 3. ASA class 1, 2 or 3 4. Signed informed consent form.

Exclusion criteria

1. Ongoing neoplasm or history of neoplasm other than breast cancer with the exception of: basal cell carcinoma, cervical carcinoma in situ, other treated cancer that has not relapsed during the 5 years preceding inclusion in the trial. 2. Axillary dissection planned during surgery planning 3. All bilateral surgery the day of Pecs administration 4. Metastatic breast carcinoma at diagnosis (M1). 5. Allergy to local anesthetics and morphine. 6. Use of analgesics during the 12 hours preceding the surgical procedure. 7. History of ipsilateral surgery during the previous 6 months. 8. History of substance abuse. 9. Pregnant woman or breastfeeding. 10. Subjects deprived of their liberty or under guardianship (including temporary guardianship). 11. Subjects no covered by social security scheme 12. Experiencing any psychiatric condition or major cognitive impairment that may hamper completion of self-reported questionnaires. There is no prohibition for people to take part simultaneously in another search and there is no exclusion cause at the end of the research period

Design outcomes

Primary

MeasureTime frameDescription
To compare the effect of ropivacaine versus placebo pectoral nerve block (Pecs 1 and 2) on acute pain after tumorectomy plus sentinel lymph node dissection on one day surgery3 hoursPercentage of patients treated with step 2 or 3 analgesics during the first three postoperative hours after tumorectomy plus sentinel lymph node dissection, between the group with Ropivacaïne and the group with placebo

Secondary

MeasureTime frameDescription
Evaluation of acute pain until 48 postoperative hours48 hoursBrief Pain Inventory Questionnaires at 48 hours will be collected with VAS Scale (0 to 10 : 0 = no pain and 10 = Worst pain possible)
Evaluation of patient's satisfaction on pain management48 hoursScale of satisfaction ( 0 to 10 : 0 = very bad and 10 = excellent) of the pain management at 48 post-operative hours
Evaluation of Remifentanil consumption during anesthesia3 hoursTotal dose of Remifentanil during anesthesia for a bispectral index between 40-60 or Analgesia Nociception Index (ANI) \> 60%
Evaluation of acute pain at rest and after shoulder movement until 48 postoperative hours48 hoursVAS Scale (0 to 10 : 0 = no pain and 10 = Worst pain possible) at rest and after shoulder movement every 30 minutes during the first three postoperative hours in the PACU and the day surgery unit and then at home every 6 hours for the first 48 postoperative hours .
Evaluation of the incidence of nausea and vomiting during the first 48 postoperative hours48 hoursIncidence of nausea and vomiting during the first 48 postoperative hours
Evaluation of complications of Pecs during 48 postoperative hours48 hoursComplications of Pecs block: pneumothorax, nerve injury, hypotension, vascular puncture and systemic toxicity of local anaesthetic (seizures, etc.) collected
Evaluation of the incidence of serious adverse events during 30 days30 daysNumber of serious adverse events during 30 days after Pecs administration
Evaluation of analgesic consumption during the first 48 postoperative hours48 hoursConsumption of Ketoprofene in systematic, Paracetamol if VAS\>3 and Tramadol if analgesia is not enough during 48 postoperative hours

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026